What are the withdrawal symptoms of clonazepam (Klonopin)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 19, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Clonazepam Withdrawal Symptoms

Clonazepam withdrawal can cause potentially life-threatening symptoms including anxiety, insomnia, tremors, sweating, nausea, vomiting, diarrhea, muscle aches, increased heart rate, and seizures, requiring careful tapering to minimize these risks. 1, 2

Common Withdrawal Symptoms

Withdrawal from clonazepam typically manifests with both physical and psychological symptoms:

Physical Symptoms

  • Increased heart rate/palpitations
  • Sweating (ranging from mild moistness to streaming sweat)
  • Tremors (mild to severe)
  • Nausea and vomiting
  • Diarrhea
  • Muscle aches and joint pain
  • Headaches
  • Weakness
  • Piloerection (goosebumps)
  • Runny nose or tearing
  • Seizures (in severe cases) 3, 1, 4

Psychological Symptoms

  • Anxiety and agitation
  • Insomnia and nightmares
  • Irritability
  • Difficulty concentrating
  • Confusion
  • Dysphoria and feelings of hopelessness
  • Depersonalization
  • Hypersensitivity to stimuli (light, sound)
  • Panic attacks 1, 4

Severity and Timeline

The severity of withdrawal symptoms depends on several factors:

  • Dosage: Higher doses lead to more severe withdrawal
  • Duration of use: Longer use (especially >1 year) increases withdrawal severity
  • Rate of discontinuation: Abrupt discontinuation causes more severe symptoms
  • Individual factors: Age, comorbidities, and concurrent medications 1, 2

Withdrawal symptoms typically begin within 24-72 hours after the last dose and may persist for weeks to months. In some cases, patients develop a protracted withdrawal syndrome with symptoms lasting more than 12 months 2.

Risk Factors for Severe Withdrawal

  • Long-term use (>1 year)
  • High doses (>1 mg/day)
  • History of substance use disorders
  • Concurrent use of other CNS depressants
  • History of seizures
  • Advanced age
  • Hepatic impairment 1, 2

Clinical Assessment

The Clinical Opiate Withdrawal Scale (COWS) can be adapted to assess benzodiazepine withdrawal severity, monitoring:

  • Vital signs (especially heart rate)
  • GI symptoms
  • Sweating
  • Restlessness
  • Pupil size
  • Anxiety levels
  • Bone/joint aches
  • Runny nose/tearing 3

Management Recommendations

To minimize withdrawal symptoms:

  1. Gradual tapering is essential:

    • For standard cases: Reduce by 0.25 mg per week 4
    • For long-term users (≥1 year): Slower tapers of 10% per month 1
    • For higher doses (>1 mg/day): Initial taper of 0.5 mg every 2 weeks until reaching 1 mg/day 1
  2. After reaching the smallest available dose (0.125 mg):

    • Extend the interval between doses before complete discontinuation 1
  3. For severe withdrawal symptoms:

    • Consider temporary pause in tapering
    • For severe agitation: Short-term use of antipsychotics may be considered (olanzapine 2.5-5 mg, quetiapine 25 mg, or risperidone 0.5 mg) 1

Important Cautions

  • Never discontinue clonazepam abruptly as this can precipitate life-threatening withdrawal reactions including seizures 2
  • Monitor closely for suicidal thoughts or behavior as these may emerge during withdrawal 2
  • Be aware of protracted withdrawal syndrome where symptoms persist for months after discontinuation 2
  • Special populations (elderly, those with respiratory conditions, hepatic impairment) require even more cautious tapering 1

Clinical Pearls

  • Withdrawal symptoms are often mistaken for recurrence of the original condition (anxiety, insomnia)
  • Patients may need reassurance that withdrawal symptoms are temporary
  • Non-pharmacological approaches for anxiety and insomnia should be maximized during tapering
  • Concurrent use of opioids significantly increases the risk of severe outcomes during withdrawal 1, 2

References

Guideline

Benzodiazepine Use and Safety

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.